Technology

• Immediate-acting AB-101 nitinol coated flow booster
• Bespoke fenestrated vascular occluder sized specifically to patient anatomy and physiology
• Proprietary design of aortic booster – patent pending
• Potentially differentiated efficacy to competitor products
• Developing for local anaesthetic insertion suitable for patients with advanced cardiopulmonary failure
• Dual benefit via combination mechanisms of action
• Robust preclinical data package with completed proof-of-concept human study
• Improved heart and lung tolerability through static design and local anaesthetic placement